Oncology Peer Review On-The-Go: Future Directions in Small Cell Lung Cancer Treatment

Podcast

In the final part of the small cell lung cancer podcast series, CancerNetwork® and Wade Iams, MD, discuss the future of treating patients with this disease.

The final episode of CancerNetwork’s 4-part series on small cell lung cancer (SCLC) welcomes back Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center. In this conversation, Iams looks to the future of SCLC treatments, touching on topics including extending response durations for patients, emerging therapies for extensive stage SCLC, exciting research on the horizon, and more.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Check out the previous podcast episodes in this series:

Recent Videos
James Ninia, MD, discussed a phase 2/3 trial seeking to answer whether complete consolidation offers more benefit than incomplete consolidation in SCLC.
Overall survival benefit was significant with complete vs incomplete consolidation therapy, but lost significance when stratified by disease burden.
James Ninia, MD, discussed treatment options for patients with extensive-stage small cell lung cancer undergoing metastasis-directed radiotherapy.
Eric Singhi, MD, and the Oncology Brothers presenting slides
Eric Singhi, MD, and the Oncology Brothers presenting slides
Eric Singhi, MD, and the Oncology Brothers presenting slides
Eric Singhi, MD, and the Oncology Brothers presenting slides
Eric Singhi, MD, and the Oncology Brothers presenting slides
The use of novel agents like tarlatamab may be “interesting” among patients with small cell lung cancer in the relapsed setting, says Gregory Peter Kalemkerian, MD.
Prophylactic cranial irradiation may not be worthwhile for treating patients with extensive-stage small cell lung cancer based on conflicting data, according to Gregory Peter Kalemkerian, MD.
Related Content
Promising phase 1 data appear to support further evaluation of ZL-1310 as a treatment for patients with extensive-stage small cell lung cancer.

DLL3-Targeted ADC Produces Responses in Previously Treated ES-SCLC

Russ Conroy
October 25th 2024
Article

Promising phase 1 data appear to support further evaluation of ZL-1310 as a treatment for patients with extensive-stage small cell lung cancer.

Practices are on the cusp of better understanding small cell lung cancer that in turn can help to advance treatment strategies for patients, says Gregory Peter Kalemkerian, MD.

Updated ASCO Guidelines for Optimal Small Cell Lung Cancer Management

Gregory Peter Kalemkerian, MD
March 25th 2024
Podcast

Practices are on the cusp of better understanding small cell lung cancer that in turn can help to advance treatment strategies for patients, says Gregory Peter Kalemkerian, MD.

Developers plan to submit a supplemental NDA for this combination as a first-line maintenance therapy for ES-SCLC in the first half of 2025.

Lurbinectedin Combo Yields Significant OS/PFS in ES-SCLC

Roman Fabbricatore
October 15th 2024
Article

Developers plan to submit a supplemental NDA for this combination as a first-line maintenance therapy for ES-SCLC in the first half of 2025.

In episode 3 of a 4-part small cell lung cancer podcast series, Wade Iams, MD, highlights practical considerations for treating patients with small cell lung cancer, including managing toxicities and the impact of treatment on a patient’s quality of life.

Oncology Peer Review On-The-Go: Practical Considerations for Small Cell Lung Cancer Therapeutic Options

Matthew Fowler;Wade Iams, MD
December 16th 2021
Podcast

In episode 3 of a 4-part small cell lung cancer podcast series, Wade Iams, MD, highlights practical considerations for treating patients with small cell lung cancer, including managing toxicities and the impact of treatment on a patient’s quality of life.

Data show that twice-daily radiotherapy may confer improved survival vs once-daily radiation in patients with limited-stage small cell lung cancer.

Concurrent Chemoradiation/Atezolizumab Does Not Improve Survival in LS-SCLC

Russ Conroy
October 3rd 2024
Article

Data show that twice-daily radiotherapy may confer improved survival vs once-daily radiation in patients with limited-stage small cell lung cancer.

BMS-986012 in combination with nivolumab/chemotherapy showed numerical PFS improvements in those with and without brain metastases at baseline.

Novel Monoclonal Antibody Combo Shows Modest PFS Benefit in Extensive-Stage SCLC

Kristi Rosa
September 13th 2024
Article

BMS-986012 in combination with nivolumab/chemotherapy showed numerical PFS improvements in those with and without brain metastases at baseline.